Health Claims Substantiation

EEA Joint Committee Decision 21/2026 Incorporates EU Health-Claim Refusal Regulation 2025/2222

Effective 7 February 2026, the EEA Joint Committee has incorporated Commission Regulation (EU) 2025/2222—refusing authorisation of a specific disease-risk-reduction health claim for Joselito ham—into Annex II of the EEA Agreement, with Liechtenstein exempted. This alignment closes the gap for this health claim in Iceland and Norway, signalling that EEA food labelling and marketing rules will continue to mirror EU nutrition and health-claims decisions and reinforcing the need for tight central control of brand-specific claims.

23 May 2026, 08:48eur-lex.europa.euEuropean Economic Area

Japan CAA Publishes Internet Monitoring Results and Improvement Guidance on False Health Food Claims (Jan–Mar 2026)

In May 2026, Japan’s Consumer Affairs Agency published results of its January–March 2026 internet monitoring of health-food advertising, issuing improvement guidance to 156 businesses over misleading health claims under the Health Promotion Act. This enforcement signal highlights continued scrutiny of online health-food marketing in Japan, so brands and platforms should reassess claims for compliance and prepare for ongoing monitoring and potential orders if issues persist.

15 May 2026, 13:35caa.go.jpJapan

Taiwan MOHW Proposes Revised Evaluation Method for Lipid-Regulating Health Food Claims

Taiwan’s Ministry of Health and Welfare has released a draft revision of the clinical evaluation method for lipid‑regulating health food claims and opened a 60‑day public consultation from its May 2026 gazette publication. If adopted, the clarified standards for trial design, lipid endpoints, statistical power and allowable claim wording will raise the evidentiary bar for companies seeking lipid‑regulating health food approvals in Taiwan.

7 May 2026, 20:01fda.gov.twTaiwan

UK ASA Upholds Complaint Against Garnier ‘Clinically Proven’ Hyperpigmentation Claim

In April 2026 the UK Advertising Standards Authority upheld a complaint against L’Oréal UK over a Garnier Vitamin Cg Serum ad claiming it was “clinically proven” to reduce hyperpigmentation in two weeks, finding the supporting clinical trial and ingredient data too weak and unrepresentative of typical UK use. This ruling reinforces that cosmetics and personal care brands making “clinically proven” efficacy claims in the UK must hold robust, well‑designed and locally relevant clinical evidence, or risk ads being banned and future campaigns forced to tighten claim wording and substantiation.

28 Apr 2026, 19:50asa.org.ukUnited Kingdom

Bavarian Higher Administrative Court Confirms OMEGAlife Omega-3 Product Is a Food Supplement, Not a Medicinal Product

The Bavarian Higher Administrative Court ruled in March 2026 that Omega-3 supplements with nutrient levels achievable through a standard diet must be classified as food supplements rather than medicinal products. This decision sets a strict precedent for functional medicinal status in Germany, increasing the burden on manufacturers to demonstrate unique metabolic effects to secure pharmaceutical classification and reimbursement.

4 Apr 2026, 10:32gesetze-bayern.deGermany

Japan CAA Confirms 31 March 2026 Reporting Deadline and Enforcement for Functional Claims Foods

Japan has confirmed a strict March 2026 deadline for mandatory self-check reporting on functional claims foods to ensure manufacturing and quality compliance. Failure to report will trigger public database flagging and the loss of health claim status, requiring immediate internal audits to protect market access and brand reputation.

28 Mar 2026, 20:33caa.go.jpJapan

China SAMR Orders Half-Year Cleanup of Prompt Language in Advertising

China has initiated a six-month nationwide enforcement campaign targeting misleading advertising disclosures and inadequate risk warnings for complex and regulated products. Businesses should prioritize auditing marketing materials to ensure statutory warnings and limiting conditions are prominent and substantiated to avoid significant administrative penalties.

28 Mar 2026, 20:32samr.gov.cnChina

US FDA Issues Online Advisory Letter to Divine Rx Nutrition for Disease-Claim Supplements

The FDA issued an advisory letter to Divine Rx Nutrition for marketing supplements with unapproved disease-treatment claims, classifying them as illegal new drugs. This action signals continued aggressive enforcement against online health-claim violations, requiring firms to strictly audit digital marketing and labeling to mitigate regulatory risk.

27 Mar 2026, 18:39fda.govUnited States

US FDA Issues Online Advisory Letter to Bodynplant Over Unapproved Serious Disease Treatment Claims

The US FDA has intensified enforcement against online retailers marketing unapproved products with claims to treat serious diseases. Companies must audit digital marketing and labeling to ensure health claims do not trigger regulatory reclassification, risking enforcement and public blacklisting.

27 Mar 2026, 18:39fda.govUnited States

Netherlands Council Of State Refers Food Supplement–Medicine And Online Review Questions To CJEU (ECLI:NL:RVS:2026:1651)

The Dutch Council of State has referred questions to the CJEU to define the legal boundary between food supplements and medicinal products in online retail. This ruling will determine if consumer reviews and digital presentation can trigger pharmaceutical-level liability, reshaping compliance and moderation risks for health product platforms.

27 Mar 2026, 08:25uitspraken.rechtspraak.nlNetherlandsEuropean Union

Brazilian Chamber Working Group Backs Urgent Bills to Tighten Sanitary Control of Dietary Supplements

Brazil is fast-tracking legislation to significantly tighten sanitary controls and increase penalties for dietary supplement fraud and misleading advertising. Businesses should prepare for mandatory QR-code traceability, stricter liability for online marketplaces, and the potential criminalization of regulatory non-compliance.

27 Mar 2026, 07:52camara.leg.brBrazil

UK Department of Health and Social Care Updates ACBS Application Guidance and Submission Deadlines

The UK has updated submission deadlines and transitioned to a digital-only application process for the Advisory Committee on Borderline Substances through 2027. Manufacturers of specialized medical foods and supplements must align product development and reimbursement strategies with these fixed windows to ensure uninterrupted NHS market access.

25 Mar 2026, 11:44gov.ukUnited Kingdom

Brazil ANVISA Seizes Irregular Health Products At Mercado Livre Warehouse

Brazil’s ANVISA has escalated enforcement against irregular health and cosmetic products, conducting a major seizure at a leading e-commerce fulfillment center in March 2026. This move establishes a precedent for platform-level accountability, requiring manufacturers and distributors to ensure strict compliance with local registration and labeling standards to avoid supply chain disruptions.

24 Mar 2026, 11:38gov.brBrazil

Vietnam Abolishes Pre-Market Approval for Cosmetic Advertising

Vietnam has transitioned from pre-market approval to a post-market surveillance regime for cosmetic advertising as of February 2026. Companies must now strengthen internal compliance and maintain robust claim-substantiation files to mitigate enforcement risks under the general advertising framework.

16 Mar 2026, 15:52english.luatvietnam.vnVietnam

Japan Consumer Affairs Agency Publishes Settlement of Consumer Group Injunction on LISTERINE “No.1” Bactericidal Claims

Japan's Consumer Affairs Agency has finalized a settlement regarding misleading superlative marketing and efficacy claims on consumer product labeling. This enforcement underscores the need for clear substantiation of performance rankings to avoid misrepresentation risks and potential injunctions from consumer advocacy groups.

12 Mar 2026, 11:28caa.go.jpJapan

Colorado Bill SB26-066 Would Regulate Compounded Weight-Loss Medications

Colorado is advancing legislation to mandate strict manufacturing standards and safety labeling for non-FDA-approved compounded weight-loss medications. Operators must implement rigorous ingredient traceability and disclosure protocols to avoid substantial per-dose fines and potential loss of business licenses.

10 Mar 2026, 14:47leg.colorado.govUnited States

US District Court (New Jersey) Dismisses PFAS Consumer Suit Against Band-Aid For Lack Of Standing

A US Federal Court dismissed a consumer class action alleging PFAS contamination in bandages due to a lack of concrete injury or specific misrepresentation. This ruling reinforces a high evidentiary bar for PFAS litigation based on general safety marketing and economic loss theories without proof of actual harm.

10 Mar 2026, 12:54lexology.comUnited States

EFSA NDA Panel Finds Insufficient Evidence for Anxiofit‑1 Article 14 Health Claim on Anxiety Reduction

EFSA has rejected a disease risk-reduction health claim for Anxiofit-1, citing insufficient clinical evidence to link the botanical extract with reduced anxiety. This decision reinforces the high evidentiary bar for Article 14 claims, signaling that manufacturers must provide robust long-term efficacy data and clear mechanisms of action to secure EU market authorization.

9 Mar 2026, 18:26efsa.europa.euEuropean Union

EU Parliament Questions Commission on Energy Powders for Inhalation (P-000828/2026)

The European Commission has been formally challenged to clarify the regulatory status and safety of inhaled energy powders that currently evade traditional food and drug classifications. Manufacturers of novel stimulant delivery systems should anticipate increased market surveillance and potential legislative action to address consumer safety risks and marketing loopholes.

9 Mar 2026, 18:18europarl.europa.euEuropean Union

Brazil Anvisa Orders Seizure of Palmito Lemos Palm-Heart Products and Recall of Melatonin Sublingual Drops

Brazil's ANVISA has mandated the immediate seizure of Palmito Lemos canned palm hearts and the recall of specific melatonin supplements due to critical manufacturing and safety violations. These enforcement actions highlight intensified market surveillance on food safety and supplement claims, requiring immediate supply chain intervention to mitigate legal and reputational risks.

9 Mar 2026, 14:41gov.brBrazil